Powering Precision Health Summit
2019 Agenda
November 19, 2019
Barcelona, Spain Hotel Miramar
| Neurology Track | Oncology Track | |
| 8:00 AM | Welcome, Agenda & Opening Keynote “Vision to Reality: Disrupting Healthcare with Digital Biomarkers” Kevin Hrusovsky, PPH Founder & Chairman Kevin Hrusovsky, Founder & Chairman, Powering Precision Health; CEO, President, and Chairman, Quanterix |
|
| 8:40 AM | Fireside Chat with Theranos Whistleblower “Fraud is Not a Trade Secret” Tyler Schultz, CEO Flux Biosciences (Formerly Theranos) and Kevin Hrusovsky |
|
| 9:00 AM | Neurofilament Light Hot Topics Professor David Leppert, University Hospital of Basel |
Ultra-Sensitive Immunoassays for Biomarker Analysis in Clinical Samples Dr. Thomas Joos, NMI |
| 9:20 AM | Endophenotypes of Traumatic Brain Injury: What We Need to Know for the Next Generation of Clinical Trials in TBI Dr. Ramon Diaz-Arristia, Univ. of Pennsylvania |
Clinical Bioanalytical Testing Strategies of bispecific Cancer Immunotherapeutics Gregor Lotz, Roche |
| 9:40 AM | Blood NFL in brain trauma, sports concussion, and acute brain disorders Dr. Kaj Blennow, University of Gothenburg |
Nu.Q™-Capture – Enabling complete nucleosome profiling Marc Eccleston, Volition |
| 10:00 AM | pTau181:The Next NfL? Prof. Henrik Zetterberg, University of Gothenburg |
Industry perspectives on context of use and Biomarker assays John Smeraglia, UCB BioPharma |
| 10:20 AM | Coffee Break | |
| 10:40 AM | Can we rely on Serum NfL in Multiple Sclerosis Management in the Future? Dr. Jens Kuhle, University Hospital of Basel |
Practical Considerations of Using Ultra-Sensitive Single and Multiplex Biomarkers for Precision Medicine Dr. Marybeth Raines, MBBB Solutions |
| 11:00 AM | Accelerating New Treatments and Biomarkers for Parkinson’s Disease through Novel Collaborations Dr. Mark Frasier, Michael J. Fox Foundation |
Cytokines and Chemokines in the Cross-Talk Between Cancer Cells and the Immune System Prof. Rudolf Oehler, Medical Univ. of Vienna |
| 11:20 AM | Developing novel measurement tools and structured analytical data models to improve patient management decisions, create better outcomes and lower costs in MS William Hagstrom, CEO, Octave BioSciences |
Detection of type I interferons by Digital ELISA: applications in clinical and pre-clinical research Dr. Rodero Mathieu, Université Paris Descartes |
| 11:40 AM | Developing a clinical/IVD NF-L assay for worldwide patient access Dr. Andrew Beard, Siemens Healthineers |
The Power of Machine Learning in Precision Medicine – What’s Real, What’s Next Alex Lavin, Founder & CEO Latent BioSciences |
| 12:00 PM | EXPERT PANEL DISCUSSION “How can we accelerate moving Nf-L from Research to Clinic?” Dr. Jens Kuhle Dr. Mark Frasier William Hagstrom Prof. David Leppert Dr. Sebastien Kronmueller Moderator: Kevin Hrusovsky |
EXPERT PANEL DISCUSSION “Where will protein biomarkers take us in Oncology?” Dr. Marybeth Raines Prof. Rudolf Oehler Dr. Rodero Mathieu Dr. Steven Piccoli Moderator: Dr. Mark Roskey |
| 12:40 PM | Lunch | |
| 1:20 PM | Plasma Amyloid, GFAP and NfL as Predictors of Alzheimer’s Pathology Dr. Elisabeth Thijssen, Amsterdam VUMC |
Urine as a non-invasive source of biomarkers for the screening, diagnosis and prognosis of prostate cancer Dr. Irina Banzola, University Hospital Zurich |
| 1:40 PM | Investigating Alpha-synuclein as a Biomarker for Parkinson’s Disease Prof. Deniz Kirik, Lund University |
Genomics, Schenomics! Proteins Are the Cornerstone of Precision Medicine! Steve Piccoli, GlaxoSmith Kline |
| 2:00 PM | Real World Experience with Nf-L in MS Patients Dr. Rany Aburashed, Memorial Healthcare Hospital |
SU2C Patient Advocacy – From Premise to Promise Renee Nicholas, Stand up to Cancer |
| 2;20 PM | Enabling Clinical Trials of Disease-modifying Therapies for Huntington’s Disease: The Ultrasensitive Detection Revolution Lauren Byrne, Univ. College London |
Oncology byte-sized: moving towards 3bn data points, 1 decision
Laure-Anne Ventouras, McKinsey Consulting |
| 2:40 PM | Late-Breaking Results from Mass Spectrometry-based Amyloid Beta Test for Alzheimer’s Disease Dr. Joel Braunstein, C2N Diagnostics |
Detecting and targeting altered stroma to prevent and/or treat metastatic disease Dr. Ellen Puré, University of Pennsylvania |
| 3:00 PM | EXPERT PANEL DISCUSSION “Challenges and Opportunities for Blood Tests for Alzheimer’s, Parkinson’s, and ALS” Dr. Elisabeth Thijssen Prof. Henrik Zetterberg Prof. Deniz Kirik Dr. Andrea Malaspina Lauren Byrne Dr. Joel Braunstein Dr. Sara Mariotta Moderator: Kevin Hrusovsky |
A perspective on trends in bioanalytical research: from service to collaboration and innovation for Oncology Dr. David Brown, PRA |
| 3:30 PM | Coffee Break | |
| 3:40 PM | Should microglial activation be a therapeutic target in Alzheimer’s disease? Prof. Dr. Robert Perneczky, LMU Munich |
One Parents Perspective on the Promise of Precision Medicine for Pediatric Oncology Patrick Sullivan, Coast to Coast Against Cancer Foundation |
| 4:00 PM | Serum NfL as Predictor of Visual Outcome After Optic Neuritis Dr. Roberto Furlan, San Rafaele Scientific Institute |
Predictive biomarkers to guide anti-angiogenic therapy: the search continues Dr. Andrew Nixon, Duke University |
| 4:20 PM | Reverse phase protein array (RPPA) in traumatic brain injury research; the power of flexibility and throughput in discovering pathomechanisms and biomarkers Dr. Denes Agoston, Uniformed Health Services |
Personalizing checkpoint inhibitor-based cancer immunotherapy Dr. Justin Balko, Vanderbilt University |
| 4:40 PM | Antibody Development & Detection Technology Innovation — Collaborations Models to Power Precision Health Koen Dewaele, CEO – ADx Neurosciences |
The role of multi-omic profiling for treatment selection in metastatic breast cancer Dr. Mariaelena Pierobon, George Mason University |
| 5:00 PM | The Immune Response as Surrogate Biomarker of Neurodegeneration: The Example of ALS Dr. Andrea Malaspina, Univ. of London |
Multi-omic molecular tumor boards: choosing tests and implementation into clinical practice Dr. Ari VanderWalde, West Cancer Center |
| 5:20 PM | Neurology track participants are invited to attend the panel discussion in the Oncology track. | EXPERT PANEL DISCUSSION “Applying Digital Protein Biomarkers to Oncology & Immuno-Oncology: Is the time now?” Dr. Andy Nixon Dr. Justin Balko Dr. Mariaelena Pierobon Dr. Ari VanderWalde Patrick Sullivan Moderator: Kevin Hrusovsky |
| 5:50 PM | Closing Comments Kevin Hrusovsky |
|
| 6:00 PM | PPH Celebration & Cocktail Reception, All Welcome! | |